Health Care · In Vitro & In Vivo Diagnostic Substances · Nasdaq · CIK 1321834 · FYE Dec 31 · Prices AT CLOSE 2026-07-29 (USD) — end-of-day, never a live or intraday quote
Last $2.51Day −11.62%Mkt cap $20MOff 52W high −69.3%Vol (1Y) 138.0%
Daily closing price, split-adjusted to the current basis; 0.8y shown of 201 bars on file. Sampled to 201 points — every point is a real close, none averaged. Price return, not total return (dividends excluded). Source marketstack.
| Short interest20.4% of sh out |
| Days to cover7.1d |
| 13F net flow (QoQ)+2.10% |
| Top-10 13F concentration98.9% |
| Next report (est.)2026-08-15 |
Short interest is FINRA semi-monthly, settlement 2026-07-15. 13F figures are quarterly filings, period 2026-Q1 — a lower bound on true ownership.
| Earnings (TTM)-$11.7M |
| ROE−73.7% |
Screener basis: ratios from the latest reported fiscal year; Sales/Earnings are trailing twelve months in the reporting currency (USD). The P/E is a trailing FULL-YEAR P/E, not TTM. Missing lines are absent from the filings, never imputed.
| YTD−37.1% |
Total return through 2026-07-29 · series begins 2025-09-25. Only the windows this history actually covers are shown.
| Ann. volatility (1Y)138.0% |
| Ann. volatility (3Y)138.0% |
| Sharpe (1Y)0.06 |
| Sharpe (3Y)0.06 |
| Max drawdown (1Y)−63.7% |
| Max drawdown (3Y)−63.7% |
Daily simple returns, annualized; drawdown is peak-to-trough within the window. Beta is the OLS slope of monthly returns on SPY's over three years. Each figure is labeled by the window it was measured over — they are not comparable across windows.
| Manager | Shares | Value | % sh out | QoQ |
|---|---|---|---|---|
| Quinn Opportunity Partners LLC | 211,390 | $729,296 | 2.69% | +0.0% |
| JANE STREET GROUP, LLC | 126,188 | $435,348 | 1.61% | +211.7% |
| UBS Group AG | 77,989 | $269,062 | 0.99% | +347.6% |
| ADAR1 Capital Management, LLC | 50,000 | $172,500 | 0.64% | new |
| GEODE CAPITAL MANAGEMENT, LLC | 47,390 | $163,495 | 0.60% | +62.0% |
| VANGUARD CAPITAL MANAGEMENT LLC | 37,511 | $129,413 | 0.48% | new |
| HRT FINANCIAL LP | 22,404 | $77,000 | 0.29% | new |
| DIMENSIONAL FUND ADVISORS LP | 19,058 | $65,750 | 0.24% | +0.0% |
Reported 13F long positions as filed for 2026-Q1 (change vs 2025-Q4). 13F covers US-listed long equity only — the sum is a LOWER BOUND on institutional ownership, never a total.
| Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|---|---|---|---|---|
| 2026-03-31 | 2026-05-15 | −$0.19 | — | — | — |
| 2025-09-30 | 2025-11-19 | −$2.50 | — | — | — |
| 2025-06-30 | 2025-08-19 | — | — | — | — |
| 2025-03-31 | 2025-05-15 | — | — | — | — |
EPS and revenue as reported in this filer's own XBRL — our extraction of the filings, not a vendor consensus feed, and never a beat/miss claim (we carry no estimates). YoY compares the same fiscal quarter a year earlier. Next report 2026-08-15 is ESTIMATED from filing cadence (median gap 92d) — not company-confirmed.
